PMOS Replaces PCOS In Major Shift Reflecting Women’s Metabolic Health Concerns

A major hormonal disorder affecting millions of women worldwide has officially been renamed from Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS), a move experts say better reflects the complexity of the condition and could improve diagnosis and treatment. The updated terminology was published in The Lancet following years of collaboration between researchers, clinicians and patient advocacy groups.

Medical experts involved in the change argued that the previous name, PCOS, was often misleading because many patients do not actually develop ovarian cysts. According to specialists, the older terminology focused too narrowly on ovarian symptoms while failing to capture the broader hormonal, metabolic and endocrine disruptions associated with the condition. Researchers believe this misunderstanding contributed to delayed diagnoses and incomplete treatment approaches for many women.

Dr Melanie Cree, a pediatric endocrinology expert at the University of Colorado Anschutz Medical Campus and one of the authors behind the proposal, said the revised name is intended to provide a more accurate understanding of the disorder. She explained that the absence of actual cysts in many patients frequently caused confusion among both patients and healthcare providers, limiting awareness of the condition’s full impact on the body.

Also Read: Dave Coulier Lost 20 Kgs During Cancer Treatment, Now in Remission

PMOS is considered a complex hormonal and metabolic disorder that can affect multiple systems, including reproductive health, body weight, skin, mental health and insulin regulation. Experts say the condition is closely linked to metabolic syndrome, a cluster of risk factors associated with Type 2 Diabetes, heart disease and stroke. Symptoms may include irregular menstrual cycles, acne, excessive hair growth, fertility issues, weight gain and fatigue, although presentations vary widely between individuals.

According to Dr Sarah Hutto of the University of Minnesota Medical School, the name change may help shift medical attention toward the metabolic and endocrine aspects of the disorder rather than focusing only on ovarian symptoms. Health experts say this could encourage more comprehensive care involving endocrinologists, gynecologists, nutrition specialists and mental health professionals.

Although the exact cause of PMOS remains unclear, institutions such as the Cleveland Clinic say genetics, insulin resistance and obesity are believed to play important roles in its development. Treatment generally depends on individual symptoms and may include lifestyle modifications, hormonal therapy, medications to improve insulin sensitivity and fertility-related treatment where necessary. Researchers hope the new terminology will improve public understanding and lead to earlier intervention and better long-term health outcomes for patients.

Also Read: A Forgotten Summer Delight: Falsa’s Short Season And Long Nostalgia